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University of Texas Health Science Center at Houston, Houston, TX, USAA B S T R A C TBackground: The use of neoadjuvant chemotherapy (NAC) in the
treatment of advanced ovarian cancer has increased in recent years.
There is uncertainty about NAC’s effectiveness and no study of its
cost-effectiveness compared with that of standard primary debulking
surgery (PDS). Objectives: To seek answers to three important ques-
tions: 1) What is the lifetime cost of treating elderly patients with
advanced ovarian cancer, based on the primary treatment received? 2)
Are the extra costs expended by the NAC group worth any extra
survival advantage? 3) Would NAC potentially beneﬁt a particular
subgroup and serve as a cost-effective ﬁrst-line treatment approach?
Methods: A cohort of elderly women (Z65 years) with stage III/IV
ovarian cancer was identiﬁed from the Surveillance, Epidemiology
and End Results-Medicare linked database from January 1, 2000, to
December 31, 2009. Cost analysis was conducted from a payer
perspective, and direct medical costs incurred by Medicare were
integrated for each patient. Cumulative treatment costs were esti-
mated with a phase-of-care approach, and effectiveness was meas-
ured as years of survival. Incremental cost-effectiveness ratio (ICER)
and propensity-score–adjusted net monetary beneﬁt regression wasee front matter Copyright & 2015, International S
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.1016/j.jval.2015.01.005
airson@uth.tmc.edu.
ondence to: David R. Lairson, Division of Manag
Health Science Center at Houston, 1200 Presslerused to estimate the cost-effectiveness of NAC per life-year gained.
Analyses were further stratiﬁed by risk group categorization on the
basis of tumor stage, patient age, and comorbidity score. Results:
Average lifetime cost for treatment with NAC was $17,417 more than
with PDS. With only 0.1 incremental life-year gained, the ICER
estimate was $174,173. Stratiﬁcation, however, helped to delineate
the treatment effect. Patients in the high-risk subgroup incurred
$34,390 and 0.8 life-years more than did patients in the PDS subgroup,
with a corresponding ICER of $42,987. In the non–high-risk subgroup,
NAC use was dominated by PDS (more costly, less effective). Con-
clusions: Administering NAC before surgery to patients in the high-
risk subgroup was cost-effective at “normal” levels of willingness to
pay, but not for the overall sample or for patients in the non–high-risk
subgroup.
Keywords: cost-effectiveness, neoadjuvant chemotherapy, primary
debulking surgery, ovarian cancer.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Ovarian cancer accounts for only 3% of all cancers in women in the
United States [1], yet it is the leading cause of death from
gynecologic malignancies, with elderly women experiencing a
signiﬁcantly greater burden of this disease [2]. Despite a 5-year
survival rate of 95% in women with stage I disease, 60% to 75% of
the cases are diagnosed at an advanced stage, wherein survival is
dramatically reduced to about 30%; a poor prognosis [2,3]. Primary
debulking surgery (PDS) followed by adjuvant chemotherapy (AC)
has remained the standard approach to treat advanced stage III/IV
ovarian cancer for decades. Surgical debulking is the standard
treatment for this malignancy, with its success lying in optimallyreducing the macroscopic tumor lump to less than 1 cm in size.
More recently, experts report that optimal resection entails no
macroscopic tumor residue after surgery [4]. Clinical character-
istics (e.g., bulky unresectable tumor or poor performance status),
however, often present a challenge in performing optimal ﬁrst-line
surgical resection and patients may instead be given neoadjuvant
chemotherapy (NAC) before debulking surgery; that is, a few cycles
of chemotherapy are followed by delayed debulking surgery [5].
This method helps to overcome the surgical difﬁculties of treating
complex disease and reduces the tumor to a manageable size for
optimum cytoreduction.
The effectiveness of NAC versus PDS has been studied over
the last two decades. Studies have highlighted the mixed effectsociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 8 7 – 3 9 5388of NAC on survival and perioperative morbidity, but were limited
to nonrandomized small sample or retrospective evaluations (see
Onda and Yoshikawa [6] for a review). A meta-analysis of 22
cohorts reported that platinum-based NAC was associated with
inferior overall survival compared with PDS-AC [7]. In contrast, a
subsequent meta-analysis concluded that NAC reduced the risk
of suboptimal surgery by half and may also help gynecologic
oncologists enhance the rate of optimal cytoreduction [8]. Find-
ings from meta-analyses are dependent on the kind of studies
included, as well as different statistical analysis performed. The
age of patients included in these studies ranged from 53 to 68
years and may not be generalizable to elderly women (i.e., 65þ
years). Of four prospective randomized phase III trials initiated to
date [9–12], results from the European Organisation for Research
and Treatment of Cancer (EORTC) and Medical Research Council-
Chemotherapy or Upfront Surgery in Ovarian Cancer Patients
trials have reported noninferior survival with signiﬁcantly less
morbidity in patients with stage IIIc/IV cancer receiving NAC
[9,11]. Although other phase III trials are underway, exploratory
subgroup ﬁndings from the EORTC trial reveal that patients with
stage IV cancer and bulky metastatic tumors may have a longer
survival from NAC [13]. Although members of the Society of
Gynecologic Oncologists in the United States are not fully con-
vinced of NAC as a treatment option [14], population-based
evidence has shown that from 1995 to 2005 there has been a
small decline in the use of PDS, with a corresponding increase in
the odds of use of NAC in elderly patients with ovarian cancer
[15]. Almost 14% of advanced cases (n ¼ 6844) received NAC and
experienced fewer postsurgical complications than did those
receiving PDS [16]. Thus, we anticipate a slow growing use of
NAC in routine clinical practice. An aging population and possible
change in treatment paradigm over the years can be expected to
contribute to the strain on Medicare resources. Because admin-
istering chemotherapy before debulking will likely increase
health care utilization, concerns about cost-effectiveness will
likely arise, despite favorable outcomes for some patients.
Economic evaluations within the realm of ovarian cancer have
largely centered on cost-effectiveness studies evaluating various
chemotherapeutic agents for de novo [17–24] and recurrent [25–
30] cases of cancer or assessing the value of intraperitoneal
chemotherapy compared with intravenous administration
[31,32]. Most of the cost-effectiveness estimates were based on
modeling approaches using several data sources and results from
clinical trials. Economic assessment involving the use of NAC in
ovarian cancer has not been explored, despite its anticipated
increasing use in community practice. We sought answers to
three important questions: 1) What is the lifetime cost of treating
elderly patients with advanced ovarian cancer, based on the
primary treatment received? 2) Are the extra costs expended by
the NAC group worth any extra survival advantage? 3) Would
NAC potentially beneﬁt a particular subgroup and serve as a cost-
effective ﬁrst-line treatment approach?Methods
Data Source, Cohort Selection, and Treatment Identiﬁcation
This was a retrospective cohort study that used data from the
Surveillance, Epidemiology and End Results (SEER)-Medicare
linked database [33,34]. We included women 65 years or older
and newly diagnosed with advanced stage III/IV epithelial ovar-
ian cancer from January 1, 2000, to December 31, 2009, with their
Medicare claims through 2010 (n ¼ 8188). For information on
SEER-Medicare data and details on the cohort selection, see
Appendix A in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2015.01.005. Treatment received was identiﬁedon the basis of ﬁrst claim after ovarian cancer diagnosis from
Medicare claims data. Cases with no evidence of surgery or
chemotherapy within 12 months of diagnosis were excluded
(n ¼ 1810). Patients receiving surgery as ﬁrst-line treatment
within 12 months from diagnosis (may or may not be given AC)
were classiﬁed as having received PDS and were identiﬁed from
Medicare claims or from cancer-directed surgery codes in SEER
data. Although our PDS deﬁnition may be less stringent than that
used in trials [10], a frequency distribution for cancer-directed
surgery codes showed that most of the patients belonged to code
60 (debulking; cytoreductive surgery, not otherwise speciﬁed; n ¼
1340) or code 61 (with colon [including appendix] and/or small
intestine resection [not incidental]; n ¼ 1208). None of the
patients in our study had SEER-surgery codes 10-16, 20-22, or
30-32, which may be more characteristic of surgery for early stage
ovarian cancer. Hence, our deﬁnition for PDS would match
closely with that used in clinical trials. Patients receiving chemo-
therapy as ﬁrst-line treatment within 12 months of diagnosis and
before the date of surgery were classiﬁed as having received NAC
(see Appendix A, Tables 2–4, in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.01.005 for codes used to
deﬁne PDS and NAC). Patients who did not receive surgery after
primary chemotherapy were excluded (n ¼ 1535).
Data Analysis
Patient characteristics were described by primary treatment, with
statistically signiﬁcant differences identiﬁed using t tests for con-
tinuous variables and chi-square tests for categorical variables.
Treatment assignment is not randomized in routine clinical care,
and there may be baseline differences in patient and clinical
characteristics. Traditionally used multivariate-regression methods
that adjust for confounding bias pose a threat in situations in which
there is lack of overlap between treatment groups. Patients with
complete contraindications and those with absolute indications for
the treatment are not easily identiﬁed with the conventional
method, leading to model-misspeciﬁcation and biased estimates
of treatment effects [35,36]. Hence, we used the propensity score
(PS) method to adjust for baseline characteristic differences
between treatment groups when evaluating cost, effectiveness,
and cost-effectiveness measures. PS is the conditional probability
of being treated given the observed baseline covariates [37]. Using
the logistic regression model, a PS was estimated to predict the
probability of treatment assignment (dependent variable) for each
patient from covariates listed in Table 1. Quintiles of PS were
computed to stratify patients into mutually exclusive groups, so
that across strata, patients with either treatment alternative have a
similar distribution of measured covariates. This method can
eliminate almost 90% of the bias owing to unbalanced treatment
groups [38], and hence can provide better control of bias over
traditional multivariate regressions. Considerable overlap was seen
in plots of PS distribution for both treatment groups, and the last
column in Table 1 shows that after adjustment with PS quintiles,
balance was achieved in the distribution of covariates between
treatment groups. Computer programming and analysis were
carried out using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
Estimating Costs
Total treatment costs were estimated starting from the date of
diagnosis until death or last available Medicare claims (December
2010), using the phase-of-care approach [39]. This method is
popularly used to estimate costs in the presence of censored
data [40,41], wherein the period between cancer diagnosis and
death was divided into three phases of care—initial, continuing,
and terminal—depending on patient survival time (see Appendix
A, Table 7, in Supplemental Materials found at http://dx.doi.org/
Table 1 – Distribution of covariates in patients with advanced ovarian cancer by primary treatment.
Variable Total NAC PDS P value
(n ¼ 4843) (n ¼ 591) (n ¼ 4252) Before PS
adjustment
After PS
adjustment
Sociodemographic characteristics
Age (y)
Mean (range) 74.8 (65-100) 74.1 (65-97) 74.9 (65-100)
65–69 1101 (22.8) 149 (25.2) 954 (22.4) 0.0203 0.7029
70–74 1383 (28.6) 191 (32.3) 1192 (28.0)
75–79 1320 (27.3) 145 (24.5) 1175 (27.6)
80–84 738 (15.2) 80 (13.5) 658 (15.5)
85þ 299 (6.2) 26 (4.4) 273 (6.4)
Race
White 4474 (92.4) 535 (90.5) 3939 (92.6) 0.0695 0.9228
Nonwhite 369 (7.6) 56 (9.5) 313 (7.4)
Marital status
Married 2301 (47.5) 296 (50.1) 2005 (47.1) 0.4017 0.9160
Nonmarried 2389 (49.3) 288 (48.7) 2101 (49.4)
Median household income
First quartile (high) 1157 (23.9) 169 (28.6) 988 (23.2) 0.0308 0.5325
Second quartile 1157 (23.9) 139 (23.5) 1018 (23.9)
Third quartile 1156 (23.9) 129 (21.8) 1027 (24.1)
Fourth quartile (low) 1167 (24.1) 129 (21.8) 1038 (24.4)
Clinical characteristics
Stage
Stage III 2725 (56.3) 274 (46.4) 2451 (57.6) o0.0001 0.5690
Stage IV 1576 (32.5) 255 (43.1) 1321 (31.1)
Stage distant NOS 542 (11.2) 62 (10.5) 480 (11.3)
Histology
Serous 3252 (67.1) 371 (62.8) 2881 (67.8) 0.0157 0.5192
Other epithelial 1591 (32.8) 220 (37.2) 1371 (32.2)
Grade
Well/moderately differentiated 742 (15.3) 55 (9.3) 687 (16.2) o0.0001 0.0878
Poorly/undifferentiated 3136 (64.7) 332 (56.2) 2804 (65.9)
Not determined/stated/applicable 965 (19.9) 204 (34.5) 761 (17.9)
Comorbidity
0 2969 (61.3) 377 (63.8) 2592 (61.0) 0.1970 0.7819
1 1177 (24.3) 146 (24.7) 1031 (24.2)
2 420 (8.7) 42 (7.1) 378 (8.9)
3þ 277 (5.7) 26 (4.4) 251 (5.9)
Year of diagnosis
2000–2001 956 (19.7) 94 (15.9) 862 (20.3) 0.0002 0.4657
2002–2003 988 (20.4) 95 (16.1) 893 (21.0)
2004–2005 882 (18.2) 109 (18.4) 773 (18.2)
2006–2007 1035 (21.4) 145 (24.5) 890 (20.9)
2008–2009 982 (20.3) 148 (25.0) 834 (19.6)
Access
SEER area
Northeast 1099 (22.7) 135 (22.8) 964 (22.7) 0.0003 0.7837
South 926 (19.1) 101 (17.1) 825 (19.4)
Midwest 633 (13.1) 50 (8.5) 583 (13.7)
West 2185 (45.1) 305 (51.6) 1880 (44.2)
Locality type
Big metro/metro/urban 4369 (90.2) 545 (92.2) 3824 (89.9) 0.0802 0.6947
Less urban/rural 474 (9.8) 46 (7.8) 428 (10.1)
Treatment facility
NCI comprehensive cancer center 368 (7.6) 90 (15.3) 278 (6.5) o0.0001 0.0656
Other facility with o300 beds 1394 (28.8) 145 (24.5) 1249 (29.4)
Other facility with Z300 beds 2997 (61.9) 351 (59.4) 2646 (62.2)
Note. Values are n (%).
NAC, neoadjuvant chemotherapy; NCI, National Cancer Institute; NOS, not otherwise speciﬁed; PDS, primary debulking surgery; PS, propensity
score; SEER, Surveillance, Epidemiology and End Results.
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of costs by phases). We incorporated total health care costs
compared with only cancer-related expenditures because it gives
a complete indicator of health care burden in elderly patients
with cancer. Direct medical costs, using Medicare payments
(rather than billed charges), were identiﬁed from claims data
and adjusted to 2009 constant dollars using Centers for Medicare
& Medicaid Services adjusters for geographic variation and
inﬂation over time, for both Part A and Part B claims (for details
on Centers for Medicare & Medicaid Services adjusters, see Brown
et al. [40]). Cumulative reimbursement amounts were added from
various Medicare ﬁles and allocated to appropriate phases to
determine phase-speciﬁc costs for each patient. Lifetime costs
were estimated for both treatment groups by combining the
mean phase-speciﬁc costs weighted with the survival function
[42]. Costs were also segregated by major cost categories (e.g.,
surgery-related hospital, physician, and complications costs and
chemotherapy and related adverse effects costs) to examine any
potential cost category inﬂuencing treatment group differences
(see Appendix A, Tables 5 and 6, in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2015.01.005 for codes).
Estimating Effectiveness
Effectiveness was measured as the observed improvement in
overall survival between treatment alternatives, wherein patients
were followed from diagnosis until death or end of the follow-up
period (December 31, 2011). Patients not experiencing the event
(death) by this date were censored. Parametric regression models
(using LIFEREG in SAS) were also run to estimate treatment effect
on survival. The results obtained using parametric models were
comparable to that obtained using the Kaplan-Meir method and
hence not reported. In addition, the effect of treatment on
survival was compared within each stratum of the PS quintile
and the average treatment effects were estimated using the Cox
proportional hazards regression, adjusting for PS.
Estimating Cost-Effectiveness
From a payer perspective (i.e., Medicare), we estimated incre-
mental cost-effectiveness ratios (ICERs) and net monetary bene-
ﬁts (NMBs) to assess the cost-effectiveness of NAC [43–46],
measured per life-year gained.1. ICER: Using average and median values of costs and effective-
ness, we estimated mean and median ICER as the ratio of the
difference in average (or median) costs to the difference in
average (or median) life-years between two treatment alter-
natives. Conﬁdence intervals (CIs) for ICERs were estimated
using nonparametric bootstrapping, with 2.5th and 97.5th
percentiles of the bootstrap samples used as an approxima-
tion of the 95% CI.2. NMB: For each patient with ovarian cancer, a net beneﬁt (NB)
value was calculated before regression, for varying
willingness-to-pay (WTP) values (λ). Several NB regression
models were then run to obtain crude and PS-adjusted
estimates for incremental NB (NBNAC  NBPDS), each with a
different value for λ.
NB ¼ (Willingness to pay  Effect) – cost ¼ λbi – ci
Crude model: NB ¼ β0 þ βTX(TXi) þ εi
PS-adjusted model: NB ¼ β0 þ βTX(TXi) þ Σβj X(j) þ εi
In the above equations, TXi indicates treatment group (TX ¼ 0
for PDS and TX ¼ 1 for NAC), bi represents years of survival, ci
indicates total costs for patient i, X(j) indicates a vector ofcovariates that include PS, and βTX represents the incremental
NB. Cost and effectiveness measures were discounted at an
annual 3% rate. Cost-effectiveness acceptability curves were
graphed to assess uncertainty in NMB estimates. A curve of the
probability that NAC is cost-effective was plotted against a series
of WTP thresholds.
Subgroup Analysis
Although prognosis of ovarian cancer is highly dependent on
residual tumor mass after surgery, postoperative outcomes vary
on the basis of stage, age, and comorbidity score of the patient
[47,48]. Hence, to explore the potential heterogeneity of effects,
women were also grouped into a high-risk category (age 75þ
years and stage IV or age 75þ years, stage III/advanced stage and
comorbidity score Z1) or a non–high-risk category that we
adapted from previously published criteria [16,48], and the value
of NAC was determined for these subgroups separately.Results
Of 4843 women who met the study eligibility criteria, 12% (n ¼
591) received NAC before surgery and 88% (n ¼ 4252) received PDS
with/without AC. Although half the study population comprised
nonmarried women (49%) aged 75 years and older (49%), the
majority of the study population was white (92%). Most patients
were diagnosed with stage III (56%), serous epithelial histology
(67%) tumor. Table 1 presents patient characteristics for the
overall sample and by treatment received. Although signiﬁcant
differences between the treatment groups were observed for
most baseline covariates, they were similar based on race,
marital status, comorbidity score, and locality type. Compared
with patients receiving NAC, patients receiving PDS more com-
monly presented with stage III (58% vs. 46%) and well to
moderately differentiated grade tumor (16% vs. 9%).
Table 2 presents average and median health care costs by
phase of care and treatment group. Observed costs (undiscounted
and 3% discounted) in the continuing phase were higher than in
initial and terminal phases. Cumulative lifetime costs were higher
for the NAC group (mean $134,576; median $123,595) than for the
PDS group (mean $117,159; median $100,747). After accounting for
censoring, there was an increase in continuing phase costs,
resulting in an increase in mean and median lifetime costs by
$38,851 and $21,074 for the NAC group and $51,137 and $20,256 for
the PDS group, respectively. On comparing cost categories, it was
found that patients receiving NAC incurred signiﬁcantly lower sur-
gical complication costs ($4987; P ¼ 0.0007), but higher chemo-
therapy ($6874; P o 0.0001) and chemotherapy-related adverse
effects costs ($4604; P ¼ 0.0001) in the 12 months after diagnosis,
after adjusting for PS. No signiﬁcant differences were observed for
surgery-related hospital (P ¼ 0.2826) and physician (P ¼ 0.1572) cost
categories (see Appendix B, Table 1, in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.01.005).
Crude and adjusted overall survival was compared across
treatment groups in Figures 1 and 2 and Table 2 in Appendix B
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2015.01.005. NAC did not improve survival, for the entire
sample and also within strata of PS quintiles (PS-adjusted hazard
ratio ¼ 0.947; 95% CI 0.855–1.049). A very small difference was
observed in mean and median overall survival between patients
who received NAC (mean life-years ¼ 3.1, median life-years ¼ 2.4)
and patients who received PDS (mean life-years ¼ 3.0, median
life-years ¼ 2.1). The results for the cost-effectiveness of NAC
using the ICER and NMB approach are presented in Table 3. For
each life-year gained, the mean and median ICER for the NAC
group compared with the PDS group was $174,173 and $76,160,
Table 2 – Total health care cost* based on phase-of-care approach.
Treatment n Observed mean
costs ($)
Estimated mean
costs ($)
Observed median
costs ($)
Estimated median
costs ($)
Undiscounted 3%
discount
rate
Discounted &
weighted with
survival
Undiscounted 3%
discount
rate
Discounted &
weighted with
survival
Initial-phase cost
NAC 569 47,502.7 47,179.1 48,348.6 45,534.4 45,296.1 44,419.6
PDS 3,388 49,126.2 48,912.9 45,420.2 45,685.4 45,426.6 38,261.5
Continuing-phase cost
NAC 510 67,123.3 63,469.7 88,007.0 50,606.4 48,786.4 69,048.1
PDS 2,983 68,784.5 64,111.2 69,741.2 47,591.5 45,156.4 49,865.5
Terminal-phase cost
NAC 471 45,422.9 43,142.6 37,072.2 40,285.8 37,099.3 31,201.4
PDS 3,463 42,728.9 40,773.8 53,134.2 35,161.0 33,320.7 32,875.9
Lifetime total costs
NAC 591 139,858.1 134,576.3 173,427.7 127,871.7 123,595.4 144,669.1
PDS 4,252 122,199.9 117,159.0 168,295.6 103,754.0 100,747.3 121,002.9
Note. Appendix A outlines the steps used to obtain the values in this table.
NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery.
* Adjusted for geographic variation and inﬂation over time.
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point estimates. The NMB regression analyses show that admin-
istering NAC is not cost-effective at lower WTP thresholds.
Negative NMBs were obtained if the payer’s WTP was $100,000
or lower per life-year. Although there may be a positive NMB if the
WTP per life-year is at least $200,000 or higher, the estimates lack
precision given the wide CI. The corresponding cost-effectiveness
acceptability curve displayed in Figure 1 depicts this uncertainty.
For example, at a WTP of $100,000 there is a 42% chance that the
intervention is cost-effective, whereas at a WTP of $200,000 the
probability of NAC being cost-effective increases to 72%.
Subgroup analysis results are presented in Table 4. About 30%
of the total sample (n ¼ 1452) comprised a high-risk group and
the remaining 3391 women belonged to the non–high-risk group.
Figure 3 in Appendix B in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2015.01.005 shows signiﬁcant survival
beneﬁts using NAC in the high-risk subgroup (mean incremental
effectiveness ¼ 0.8 years), with a corresponding incremental
mean health care cost of $34,390. The mean and median ICER
for NAC in the high-risk subgroup was estimated as $42,987 (95%
CI $28,150–$66,169) and $27,332 (95% CI $22,912–$49,964), respec-
tively. In contrast, the mean and median ICER for the non–high-
risk subgroup indicate that the use of NAC was dominated by
PDS, owing to the observed negative survival beneﬁt and higher
cost spending. Similarly, using NMB regression we found that
treating patients in the high-risk subgroup with NAC before
surgery had positive NMBs for all WTP values of $50,000 and
above, while patients in the non–high-risk subgroup had negative
NMBs for any value that the payer was willing to spend. As seen
in Figure 2, the probability that NAC is cost-effective is less than
11% across the spectrum of WTP values for non–high-risk
patients, but holds major value when administered to high-risk
patients (i.e., 80% or higher chance of being cost-effective for all
WTP thresholds Z$50,000).Discussion
Treating elderly patients with ovarian cancer is not straightfor-
ward as evident from clinical trial data, especially as diagnosisoccurs at advanced stages and the 5-year survival rate is rela-
tively lower than for other malignancies. Controversy surround-
ing the beneﬁt of NAC has so far been limited to morbidity and
survival measures. Cost issues, however, will likely emerge as the
use of NAC will increase in clinical practice. While experts
continue to weigh the effectiveness of NAC in real world, we
undertook a cost-effectiveness analysis to inform clinical and
policy decision makers about the economic implications of NAC
in perspective. We identiﬁed a high-risk subgroup that may
potentially gain health beneﬁts from NAC use and will be an
economically attractive resource allocation from a payer
perspective.
The average total cost for patients receiving NAC was 15%
higher than for patients receiving PDS (i.e., $134,576 vs.
$117,159). Although survival analysis techniques have been used
to obtain reweighted estimators for mean health care costs, it
may result in biased estimates in the presence of censored data,
and hence investigators have discouraged its use [42,49]. Inde-
pendence between time-to-event and time-to-censoring is a key
requirement for Kaplan-Meier survival curve. The same princi-
ple, however, may not be applicable in the cost scenario because
cumulative cost-to-event and cumulative cost-to-censoring are
dependent on a patient’s unique pattern of cost accumulation.
Thus, we used the recommended phase-based costing method
to estimate lifetime costs of the entire cohort without actually
observing costs for all patients across their lifetime. After
weighting with survival, mean costs in both groups increased
(NAC ¼ $173,428; PDS ¼ $168,296), indicating that observed costs
are underestimated when observations are censored. Notably,
there was an increase in the continuing-phase costs, which may
be explained by the disease’s high recurrence rate. Almost 70%
to 90% of advanced cases are reported to experience a recur-
rence [50] wherein cancer treatment may continue invariably
longer through the continuous phase. Extensive surveillance
and many cycles of chemotherapy (maintenance or recurrence)
could potentially drive high costs in this phase. Cost studies in
Europe and Australia have estimated chemotherapeutic costs as
the prime component of total costs when treating ovarian
cancer [51,52]. Thus, when dealing with censored observations,
studying lifetime costs becomes important to estimate overall
Table 3 – Cost-effectiveness of using neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Undiscounted Discounted at 3%
Total health care
costs ($)
Mean  SD Median Mean  SD Median
NAC 139,858.1  78,964.7 127,871.7 134,576.3  73,512.0 123,595.4
PDS 122,199.9  91,545.4 103,754.0 117,159.0  85,471.1 100,747.3
Δ Cost 17,658.2 24,117.7 17,417.3 22,848.1
Effectiveness (life-years) Mean (SE) Median Mean (SE) Median
NAC 3.3 (0.1) 2.4 3.1 (0.1) 2.4
PDS 3.2 (0.1) 2.1 3.0 (0.0) 2.1
Δ Effectiveness 0.1 0.3 0.1 0.3
ICER ($) Mean ICER per LYG
(95% CI)
Median ICER per LYG
(95% CI)
Mean ICER per LYG
(95% CI)
Median ICER per LYG
(95% CI)
NAC 176,582 (2,166,732 to
3,167,860)
80,392.3 (60,582–
252,151)
174,173 (1,840,486 to
1,938,920)
76,160.3 (60,003–
250,992)
Undiscounted Discounted at 3%
NMB analysis on NAC Crude NMB (P value) PS-adjusted NMB
(P value)
Crude NMB (P value) PS-adjusted NMB
(P value)
WTP value ($ per LYG)
25,000 16,139 (o0.0001) 12,298 (0.0017) 15,265 (o0.0001) 11,516 (0.0017)
50,000 14,620 (0.0038) 9,484.8 (0.0745) 13,114 (0.0049) 8,313.4 (0.0896)
100,000 11,583 (0.2202) 3,859.2 (0.6986) 8,809.8 (0.3034) 1,907.4 (0.8327)
200,000 5,506.9 (0.7770) 7,392.0 (0.7189) 202.3 (0.9908) 10,905 (0.5558)
400,000 6,644.4 (0.8681) 29,894 (0.4795) 17,013 (0.6367) 36,529 (0.3371)
800,000 30,947 (0.7039) 74,899 (0.3840) 51,442 (0.4826) 87,777 (0.2568)
1,000,000 43,098 (0.6731) 97,402 (0.3669) 68,657 (0.4551) 113,401 (0.2429)
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; LYG, life-years gained; NAC, neoadjuvant chemotherapy; NMB, net
monetary beneﬁt; PDS, primary debulking surgery; PS, propensity score; SE, standard error; WTP, willingness to pay.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 8 7 – 3 9 5392disease burden. Segregating costs by important categories
revealed differences across treatment groups that were in the
expected direction. Surgical complication–related costs were
higher for the PDS group, which appears to be directly propor-
tional to ﬁndings from earlier studies that report higher blood
loss, blood transfusions, peri- and postoperative morbidity,
longer intensive care unit stays, and overall greater use of
hospital resources in those receiving PDS [53–57]. Similarly, an
earlier study using the SEER-Medicare data set found that
patients receiving NAC received almost twice the median num-
ber of chemotherapy cycles than did those receiving PDS [16],0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Pr
ob
ab
ili
ty
 o
f b
ei
ng
 c
os
t e
ff
ec
tiv
e
Willingness to pay thresholds 
($/life year saved)
Fig. 1 – Cost-effectiveness acceptability curve for ovewhich potentially explains the higher incurred chemotherapy
and chemotherapy-related adverse effects costs that we
observed in this group.
To our knowledge, this is the ﬁrst study to evaluate the cost-
effectiveness of administering chemotherapy before PDS in
patients with advanced ovarian cancer. With a modest increase
in cost and no meaningful survival beneﬁt, NAC is not cost-
effective for all patients. The NMB regression depicts that uncer-
tainty related to NAC use ﬂuctuates considerably as WTP varies.
For example, when WTP is within $50,000 of the ICER, the
probability of NAC being cost-effective ranges from 42% to 72%.NAC with surgery 
(undiscounted & crude)
NAC with surgery 
(undiscounted & adjusted)
NAC with surgery (discounted 
& crude)
NAC with surgery (discounted 
& adjusted)
rall sample. NAC, neoadjuvant chemotherapy.
Table 4 – Cost-effectiveness* of using neoadjuvant chemotherapy in patients with advanced ovarian cancer,
stratiﬁed by risk group.†
High risk (n ¼ 1452) Non–high risk (n ¼ 3391)
Total health care
costs ($)
Mean  SD Median Mean  SD Median
NAC 131,657.6  69,627.1 116,213.1 135,678.5  74,975.8 126,230.0
PDS 97,267.8  74,683.1 80,681.8 125,822.0  88,388.0 108,493.8
Δ Cost 34,389.8 35,531.3 9,856.5 17,736.2
Effectiveness (life-years) Mean (SE) Median Mean (SE) Median
NAC 2.9 (0.2) 2.6 3.0 (0.1) 2.3
PDS 2.1 (0.1) 1.3 3.3 (0.1) 2.4
Δ Effectiveness 0.8 1.3 0.3 0.1
ICER ($) Mean ICER per LYG
(95% CI)
Median ICER per LYG
(95% CI)
Mean ICER per LYG
(95% CI)
Median ICER per LYG
(95% CI)
NAC 42,987.2 (28,150–66,169) 27,331.8 (22,912–49,964) Dominated Dominated
NMB analysis on NAC Crude NMB (P value) PS-adjusted NMB
(P value)
Crude NMB (P value) PS-adjusted NMB
(P value)
WTP value ($ per LYG)
25,000 14,156 (0.0104) 14,398 (0.0151) 15,486 (0.0004) 11,001 (0.0156)
50,000 6,078.6 (0.4060) 4,991.6 (0.5312) 21,116 (0.0003) 14,331 (0.0180)
100,000 46,547 (0.0008) 43,770 (0.0041) 32,376 (0.0021) 20,990 (0.0552)
200,000 127,484 (o0.0001) 121,328 (0.0001) 54,895 (0.0098) 34,310 (0.1216)
400,000 289,357 (o0.0001) 276,443 (o0.0001) 99,933 (0.0215) 60,949 (0.1787)
800,000 613,104 (o0.0001) 586,672 (o0.0001) 190,010 (0.0312) 114,226 (0.2143)
1,000,000 774,978 (o0.0001) 741,787 (o0.0001) 235,048 (0.0335) 140,865 (0.2219)
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; LYG, life-years gained; NAC, neoadjuvant chemotherapy; NMB, net
monetary beneﬁt; PDS, primary debulking surgery; PS, propensity score; SE, standard error; WTP, willingness to pay.
* Using a 3% discount rate for costs and effectiveness.
† Classiﬁed on the basis of age, stage, and Charlson comorbidity index [33].
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 8 7 – 3 9 5 393On stratifying results by risk groups, signiﬁcant survival advant-
age was observed in the high-risk subgroup. This is consistent
with the EORTC trial and other retrospective studies that reported
an improved survival with the use of NAC in patients charac-
terized by stage IV tumor, older age, and poor performance status
[13,16]. The ICER for NAC in high-risk subgroup was $42,988 per
life-year saved, with corresponding NMB analysis supporting its
use as a cost-effective intervention at “normal” levels of WTP. For
a traditional $100,000 that the payer may be willing to pay, the
uncertainty associated with NAC was less than 5% for each extra0
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Fig. 2 – Cost-effectiveness acceptability curve stratiﬁedsurvival year in high-risk patients, as compared with PDS. For the
non–high-risk subgroup, however, greater health care spending
in the NAC group did not translate into any improved survival
(NAC was dominated by PDS). Combining the subgroups masks
this important ﬁnding. These results from the stratiﬁed analysis
concur with expert reports [4,58] and guidelines [59] that encour-
age the use of PDS as the standard ﬁrst-line treatment in patients
with stage II or higher cancer, while recommending the use of
NAC only for certain patient subgroups contingent on clinical
expertise. For policy purposes, ICERs have traditionally beens 
High risk sub-group 
(discounted & adjusted)
Non-high risk sub-group 
(discounted & adjusted)
by risk subgroup. NAC, neoadjuvant chemotherapy.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 3 8 7 – 3 9 5394estimated using mean values of cost and effectiveness for
alternative treatment groups. Recently, Bang and Zhao [60]
discussed the merit in also reporting the median ICER [60].
Especially in situations in which effectiveness is measured in life-
years and median survival time is an important outcome indicator,
median-based ICER provides a holistic understanding of study
ﬁndings. We observed considerable concordance in the direction
of the mean andmedian ICER for our subgroup analysis though our
full sample ﬁndings depicted considerable inconsistencies.
Although the literature lacks any comparable study, we identiﬁed
a few studies that have estimated other aspects of clinical manage-
ment. For example, using community-level data from the Mayo
clinic, Aletti et al. [61] showed that an aggressive and complex
surgical approach has a cost-effectiveness ratio of $8912 per life-
year gained compared with simple surgery in advanced ovarian
cancer [61]. Similarly, Bristow et al. [62] and Greving et al. [63] have
valued the place of varying treatment referral centers (e.g., expert
center or tertiary referral care) in advanced-stage disease, while
Lowery et al. [64] demonstrate the potential of early palliative care
intervention for recurrent disease cases.
There are important limitations to consider in this study.
Findings are restricted in generalizability based on the inclusion
criteria that were applied. Despite the use of the population-based
SEER-Medicare database, which provided a rich source of cost as
well as long-term follow-up and outcomes data, limitations inher-
ent to the nature of observational claims database are applicable (e.
g., incomplete reporting, missing claims, and inaccurate out-of-
pocket costs). Although we used PS methods to minimize potential
selection bias arising from nonrandom treatment assignment,
residual confounding due to unmeasured factors such as tumor
distribution and extent of tumor resection may exist. Given their
importance in prognosis, we recommend future studies to incorpo-
rate additional instrumental variable methods to account for some
unmeasured confounders and add robustness to our statistical
method. Finding an appropriate instrumental variable may be
challenging; however, geographic variation has been increasingly
used in comparative-effectiveness treatment studies using this data
[65–67]. To guide policy decision making, cost data reﬂect only those
that were paid by Medicare. Total treatment costs did not account
for out-of-pocket payments (e.g., co-payments or deductibles) or
nonmedical costs (e.g., patient time costs and travel costs) incurred
by patients, lacking an overall societal evaluation. Over three-
quarters of the study population, however, was older than 70 years,
and costs related to departure from the workforce may be trivial as
well as insigniﬁcant from a third-party payer perspective. Unlike
previous studies that have reported costs for only a ﬁxed duration
[51,52], we accounted for censoring to give an estimate of lifetime
costs related to treating advanced ovarian cancer and also adjusted
costs for patient and clinical characteristics. Studying lifetime
treatment cost is particularly relevant in this cohort because of
the high tumor recurrence rate, which may necessitate continual
chemotherapeutic treatment in the continuous phase of care and
contribute substantially to the overall cost of treatment. Likewise,
adverse effect costs (tangible and intangible) associated with
extended cancer treatment cannot be ignored. Although quality of
life did not signiﬁcantly differ between treatment groups for
patients enrolled in the EORTC trial [68], it would be important to
assess whether the same holds true for this population. Because
NAC provides better morbidity outcomes, including quality of life
may tend to reinforce the basic ﬁndings.
In conclusion, chemotherapy use before surgery has a favor-
able cost-effectiveness proﬁle in the high-risk group alone at
classic WTP thresholds. Its use as a general ﬁrst-line treatment in
all patients is not supported, so strengthening the role of PDS as
standard approach to treat advanced ovarian cancer. We suggest
that future studies should evaluate the role of varying chemo-
therapeutic schedules in the NAC setting.Acknowledgments
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